High Serum Level of IL-17 in Patients with Chronic Obstructive Pulmonary Disease and the Alpha-1 Antitrypsin PiZ Allele
Table 1
Clinical and laboratory parameters of groups of COPD patients, divided by the A1AT phenotype.
A1AT phenotype
PiZZ
PiMZ
PiMM
A1AT concentration (mg/l)
310.00 (191.50-463.30)
1089.00 (848.00-1464.00)
1209.00 (1084.00-685.00)
ZZ/MZ: ZZ/MM:
Age (year)
47.50 (41.25-58.0)
64.50 (57.0-70.25)
64.50 (58.50-65.50)
ZZ/MZ: ZZ/MM:
FEV1 (% predicted)
25.78 (20.35-7.76)
35.64 (24.19-41.62)
27.82 (25.35-38.91)
ns
VLC (% predicted)
61.36 (56.23-6.72)
58.17 (51.66-74.65)
50.12 (40.75-66.55)
ns
FEV1/FVC (% ratio)
30.20 (23.30-1.59)
42.72 (33.59-45.85)
48.25 (40.58-64.26)
ZZ/MZ: ns ZZ/MM:
RBC count (×109/l)
5.36 (5.08-5.79)
4.88 (4.27-5.43)
4.63 (4.36-5.19)
ns
Hemoglobin (g/l)
160.50 (149.80-174.80)
137.50 (128.00-54.80)
151.00 (141.50-158.00)
ZZ/MZ: ZZ/MM:
Hematocrit (%)
46.30 (44.0-56.55)
40.40 (38.08-42.55)
42.90 (40.60-45.75)
ZZ/MZ: ZZ/MM:
WBC count (×109/l)
7.95 (5.16-12.03)
10.38 (8.60-15.7)
12.97 (8.40-16.94)
ns
Ever-smokers/never-smokers
3/3
8/0
28/2
ns
All quantitative data are presented as interquartile range (IQR). COPD: chronic obstructive pulmonary disease; A1AT: alpha-1 antitrypsin; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; RBC: red blood cells; WBC: white blood cells.
